Serious infectious adverse events during the first 24 weeks of the ACCESS trial
| Participant | Adverse event term | Bacterial | Start | Stop | Screening | Nadir |
| Day | Day | IgG mg/dL | IgG mg/dL | |||
| 1 | Tubo-ovarian abscess | Yes | 45 | 57 | 1470 | 1140 |
| 2 | Cellulitis | Yes | 1 | 6 | 630 | 431 |
| 3 | Urinary tract infection | Yes | 0 | 5 | 493 | 493 |
| 3 | Pneumonia | Yes | 5 | 51 | 493 | 493 |
| 4 | Gastroenteritis | No | 88 | 94 | 1554 | 1025 |
| 5 | Bacteraemia | Yes | 56 | 59 | 1268 | 1268 |
| 6 | Viral infection | No | 59 | 63 | 1143 | 797 |
| 7 | Pneumonia | Yes | 7 | 11 | 852 | 690 |
| 8 | Gastroenteritis viral | No | 95 | 110 | 577 | 347 |
| 9 | Viral infection | No | 38 | 41 | 688 | 327 |
| 9 | Fever | Unknown | 116 | 118 | 688 | 327 |
ACCESS, Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.